Clinical Utility of Cxbladder for the Diagnosis of Urothelial Carcinoma.
This study aimed to demonstrate the clinical utility of non-invasive multigene Cxbladder urine tests in reducing the overall number of diagnostic tests and invasive procedures used in the clinical evaluation of patients presenting with microhematuria, a key symptom of urothelial carcinoma (UC). There is a belief that using non-invasive molecular diagnostic tests in patients with hematuria may lead to patients undergoing unnecessary and costly invasive procedures that can cause adverse events and decrease patient quality of life. The objective of this study was to determine whether or not this was the case, using Cxbladder.



Data from 396 patient-by-urologist interactions generated 792 decision points from a standardized cohort of 33 patients evaluated by 12 urologists. Participant physicians recommended a selection of tests and procedures based on referral data, then reviewed and amended their recommendations in the context of diagnostic information from Cxbladder used in the Triage and Triage and Detect clinical modalities.



All urologists changed their diagnostic behavior in at least one patient case with the addition of Cxbladder results. The total number of diagnostic procedures was reduced by 5% and 25% following disclosure of results from Cxbladder in the Triage and the Triage and Detect modalities, respectively. The total number of requested invasive procedures was reduced from 425 at referral to 379 (-11%) and 292 (-31%) following disclosure of Cxbladder information in the Triage and Triage and Detect modalities, respectively.



Urologists made compelling changes to their clinical decision-making when they were provided with Cxbladder results for patients presenting with hematuria. Cxbladder provides an increase in clinical utility by focusing the use of invasive diagnostic procedures to appropriate patients, reducing both the total number and number of invasive procedures used in the clinical management of patients with hematuria, thereby improving the diagnostic experience and outcomes for patients.



Pacific Edge Ltd.
Pacific Edge Ltd., Dunedin, New Zealand.
David
D
Darling
Pacific Edge Ltd., Dunedin, New Zealand.
Carthika
C
Luxmanan
Pacific Edge Ltd., Dunedin, New Zealand.
Paul
P
O'Sullivan
Pacific Edge Ltd., Dunedin, New Zealand.
Tony
T
Lough
Pacific Edge Ltd., Dunedin, New Zealand. jimmy.suttie@pelnz.com.
James
J
Suttie
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000652:urine*; D002277:Carcinoma / Q000175:diagnosis* / Q000235:genetics*; D015331:Cohort Studies; D005260:Female; D006417:Hematuria / Q000175:diagnosis*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012313:RNA / Q000652:urine*; D014523:Urethral Neoplasms / Q000175:diagnosis* / Q000235:genetics*
D014408:Biomarkers, Tumor; D012313:RNA
Biomarker; Clinical parameters; Clinical utility; Cystoscopy; Genotypic markers; Hematuria; Molecular diagnostic; Urine; Urothelial carcinoma